Jekkie Kim advises healthcare, life sciences, and technology companies and their investors and lenders on a range of matters related to intellectual property, technology, and data. She draws on her background as a medical doctor, and has developed a particular focus on digital health, food technology, and cross-border transactions. Dr. Kim has extensive experience with strategic licensing and commercial transactions and guides clients through resolving complex IP issues by proposing creative, efficient, and effective strategies.

Dr. Kim advises clients at all stages, from emerging companies to global market leaders, in sectors including:

  • Pharmaceutical and biotechnology
  • Digital health
  • Food technology
  • Medical devices

She advises clients on transactional matters, including:

  • Strategic licensing and collaborations
  • University spin-outs
  • Research, development, and agreements
  • Manufacturing, supply, and distribution agreements
  • Joint ventures
  • Mergers and acquisitions
  • IPOs and follow-on offerings
  • Diverse financing transactions, including royalty purchase and sales

Her medical and business knowledge and perspectives as well as her experiences as a member of the Institutional Review Board (IRB) at Massachusetts General Hospital (MGH) enables Dr. Kim to quickly understand the ins and outs of her client’s business and enables her to advise diverse clients in the most effective way.

She regularly speaks and writes on healthcare, life sciences, and digital health related topics. She is an advisor to the Stanford University SPARK Program that allows Stanford students and professors to generate drug and diagnostic proofs-of-concept for potential commercialization, using academic approaches combined with industry standards.

Dr. Kim also maintains an active pro bono practice, helping clients protect and leverage their intellectual property, technology and data rights.

Dr. Kim’s representative experience includes advising:

Strategic Intellectual Property Transactions

  • Octagon Therapeutics in its research alliance with Novo Nordisk to target discovery approach and novel chemistry strategy around inflammatory disease
  • National Resilience in a strategic alliance with The Parker Institute for Cancer Immunotherapy (PICI) to develop next-generation cancer therapies generated from PICI’s network of leading immunotherapy research centers
  • Senda Biosciences in a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for metabolic conditions, including obesity and glycemia 
  • Agenus in a US$1.85 billion collaboration to develop and commercialize up to five novel immuno-oncology treatments

Joint Ventures and M&A

  • Purigen Biosystems in its acquisition by Bionano Genomics
  • Imago BioSciences in its pending US$1.35 billion acquisition by Merck
  • CooperCompanies in its US$1.6 billion acquisition of Generate Life Sciences, and its US$875 million acquisition of Cook Medical’s Reproductive Health business
  • Pionyr Immunotherapeutics on its sale of 49.9% equity interest to Gilead Sciences for US$275 million, along with an exclusive option to purchase the remainder of Pionyr, for up to US$1.47 billion 
  • Corvus Pharmaceuticals on its joint venture with Angel Pharmaceuticals to develop and commercialize Corvus’ drug candidates in China
  • UPSIDE Foods (formerly Memphis Meats) in its acquisition of Cultured Decadence


  • Innocoll Biotherapeutics in its US$125 million term loan provided by funds managed by Oaktree Capital
  • Coherus Biosciences in its US$300 million credit financing with Pharmakon Advisors
  • Alignment Healthcare in its US$250 million senior secured term loan facility with Oxford Finance
  • Rhythm Pharmaceuticals in its US$100 million non-dilutive revenue interest financing with HealthCare Royalty Partners

Bar Qualification

  • California
  • Massachusetts
  • New York


  • J.D., Boston University School of Law
  • Masters of Business Administration, Case Western Reserve University
  • LL.M., Yonsei University Department of Medical Law and Ethics
  • MD, Yonsei University College of Medicine